Monitor for closing conditions — specifically the FDA license and CLIA certification timelines — as any delay beyond H2 2026 could signal regulatory friction. Post-close, track the acquired centers' revenue contribution and whether the $1.5M EBITDA earn-out threshold is achievable, which would provide a $1.0M cash inflow to FOXO.
Price Chart
Executive Summary
FOXO Technologies' subsidiary Vector BioSource has entered into a definitive asset purchase agreement to acquire four U.S.-based blood collection centers from a Grifols subsidiary for $3.5 million in cash at closing, plus up to $1.0 million in contingent earn-out payments. The acquisition expands FOXO's biospecimen collection business with operational assets in Miami, Philadelphia, and Memphis, though closing is subject to regulatory conditions including obtaining new FDA and CLIA licenses, with an expected close in H2 2026.
Key Financial Metrics
Key Facts
- Vector BioSource, a FOXO subsidiary, agreed to acquire four blood collection centers from Grifols Bio Supplies for $3.5M cash at closing.
- An additional earn-out payment of up to $1.0M is payable if the acquired business achieves EBITDA of $1.5M or more in any calendar year during 2026-2028.
- The acquired assets include 1,000 liters of serum, existing cell units, owned and leased real property, fixtures, equipment, permits, and donor records.
- Closing is conditioned on Vector obtaining a new and separate FDA license, CLIA certification in Tennessee, and a waste management permit from Miami city board.
- The Company anticipates closing in the third or fourth quarter of 2026; the agreement has a nine-month long-stop date.
- The acquisition is a cash transaction with no disclosed financing contingency, and the Purchase Agreement includes customary representations, warranties, and indemnification provisions.
Financial Impact
Total consideration of $3.5M upfront cash plus up to $1.0M earn-out based on EBITDA performance; no revenue or earnings figures for FOXO or the acquired business were disclosed.
Risk Factors
- Closing is contingent on obtaining new FDA and CLIA licenses, which could be delayed or denied.
- The acquired business's historical financial performance is not disclosed, making it difficult to assess the earn-out achievability.
- FOXO's ability to integrate and operate blood collection centers profitably is unproven at this scale.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-034793 |
| Document: form8-k.htm | 0001493152-26-034793 |
| Document: 0001493152-26-034793-index-headers.html | 0001493152-26-034793 |
| Document: 0001493152-26-034793-index.html | 0001493152-26-034793 |
| Document: 0001493152-26-034793.txt | 0001493152-26-034793 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 29, 2026 12w ago | 8-K | $0.0922 $0.0922 | · 0.00% | ▼ −5.53% | $0.1000 (+8.46%) |
Jul 27, 2026 13w ago | 8-K | $0.0346 $0.0884 | ▲ +155.49% | ▲ +151.38% | $0.1000 (+189.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers